porcin
epidem
diarrhea
viru
pedv
coronaviru
cov
discov
infect
intestin
tract
pig
result
diarrhea
vomit
caus
extrem
dehydr
death
neonat
piglet
asia
modifi
live
attenu
vaccin
use
control
pedv
infect
recent
year
howev
new
strain
pedv
belong
genogroup
appear
usa
quickli
spread
canada
mexico
well
asian
european
countri
due
less
effect
protect
immun
provid
vaccin
new
strain
caus
consider
agricultur
econom
loss
worldwid
emerg
new
strain
increas
import
understand
pedv
well
strategi
inhibit
coronavir
proteas
includ
main
proteas
papainlik
proteas
ideal
antivir
target
essenti
role
viral
matur
provid
first
descript
express
purif
structur
characterist
recombin
pedv
papainlik
proteas
moreov
present
find
chemotherapeut
drug
contrast
competit
inhibit
sarsand
merscov
papainlik
proteas
noncompetit
inhibitor
pedv
papainlik
proteas
discov
porcin
epidem
diarrhea
viru
pedv
coronaviru
caus
sever
agricultur
loss
chasey
cartwright
lee
pedv
infect
intestin
tract
caus
diarrhea
vomit
older
pig
mortal
pedvinfect
piglet
reach
due
extrem
dehydr
stevenson
et
al
recent
modifi
live
attenu
vaccin
pedv
genogroup
import
way
control
spread
pedv
asia
song
park
new
vaccineresist
pedv
strain
appear
usa
stevenson
et
al
sinc
new
usa
pedv
strain
later
assign
genogroup
caus
continu
pandem
north
america
europ
asia
huang
et
al
song
et
al
resist
new
pedv
strain
convent
vaccin
highlight
issu
although
vaccin
power
strategi
still
fail
due
genet
divers
epitop
genogroup
result
necessari
develop
anoth
antivir
strategi
pedv
unlik
two
highli
pathogen
human
cov
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
belong
beta
group
pedv
belong
alpha
group
chan
et
al
like
cov
pedv
depend
proteas
includ
main
proteas
pro
papainlik
proteas
pl
pro
cleav
polyprotein
alpha
cov
papainlik
proteas
pro
papainlik
proteas
pro
lee
wojdyla
et
al
polyprotein
cleavag
requir
viral
matur
thu
proteas
ideal
antivir
target
bacha
et
al
cheng
et
al
chou
et
al
kumar
et
al
lin
et
al
park
et
al
ratia
et
al
wu
et
al
furthermor
contrast
highli
variabl
spike
protein
target
antibodi
li
et
al
li
et
al
wang
et
al
wu
et
al
proteas
conserv
structur
catalyt
function
may
serv
gener
target
across
differ
cov
baileyelkin
et
al
chou
et
al
ho
et
al
ratia
et
al
yang
et
al
like
coronavir
pl
pro
pedv
pro
deubiquitin
dub
proteas
also
multifunct
protein
play
role
regul
host
antivir
immun
respons
chaudhuri
et
al
clementz
et
al
mielech
et
al
xing
et
al
zheng
et
al
dub
activ
pro
requir
suppress
host
immun
block
type
interferon
signal
howev
structur
characterist
detail
catalyt
mechan
pedv
pro
still
unclear
strategi
inhibit
accord
sequenc
align
fig
homolog
model
pedv
pro
may
compos
four
domain
ubiquitinlik
ubl
palm
thumb
finger
domain
latter
three
domain
form
catalyt
core
may
retain
catalyt
activ
like
sarsand
merscov
pl
pro
chou
et
al
clasman
et
al
lei
et
al
present
studi
made
recombin
catalyt
core
pedv
pro
demonstr
secondari
tertiari
quaternari
structur
characterist
studi
suggest
pedv
pro
exhibit
much
higher
dub
activ
sarsand
merscov
pl
pro
inhibit
antileukemia
drug
found
abl
inhibit
multipl
dub
enzym
includ
human
well
sarsand
merscov
pl
pro
chen
et
al
cheng
et
al
chou
et
al
chuang
et
al
lin
et
al
inhibit
assay
dock
simul
use
clarifi
detail
inhibit
mechan
pedv
pro
find
increas
understand
structur
catalyt
activ
pedv
pro
identifi
first
potent
inhibitor
enzym
code
sequenc
usa
strain
pedv
pro
ubl
catalyt
domain
genbank
access
number
polyprotein
residu
fullgen
synthes
genom
co
taiwan
cdna
pro
digest
ndei
xhoi
insert
express
vector
respect
catalyt
core
pro
residu
primer
use
polymeras
chain
reaction
product
digest
xhoi
ligat
phd
vector
histag
sumo
sequenc
nterminu
lee
et
al
primer
sequenc
sitedirect
mutagenesi
mutant
read
frame
plasmid
verifi
dna
sequenc
express
vector
transform
e
coli
cell
novagen
cultur
grown
lb
medium
absorb
nm
reach
cell
induc
mm
thiogalactopyranosid
incub
h
centrifug
cell
pellet
suspend
lysi
buffer
mm
triscl
ph
mm
nacl
glycerol
triton
mm
lyse
sonic
next
crude
lysat
centrifug
rpm
min
solubl
lysat
incub
ml
ninta
agaros
slurri
qiagen
co
usa
h
unbound
lysat
remov
bead
wash
wash
buffer
mm
triscl
ph
mm
nacl
mm
imidazol
mm
bead
histag
protein
bound
transfer
ml
cut
buffer
mm
triscl
ph
mm
nacl
mm
mg
ad
mixtur
incub
h
remov
sumo
fusion
final
unbound
pedv
pro
catalyt
core
load
onto
gelfiltr
column
ge
healthcar
equilibr
run
buffer
mm
triscl
ph
mm
nacl
mm
dithiothreitol
protein
fraction
check
puriti
use
sdspage
fraction
contain
protein
band
correct
size
pool
concentr
use
amicon
filter
millipor
mgml
protein
glycerol
flashfrozen
liquid
nitrogen
store
typic
yield
protein
mg
per
liter
cell
cultur
jasco
spectropolarimet
use
analyz
secondari
structur
recombin
pedv
pro
concentr
mgml
mm
phosphat
buffer
ph
use
cd
scan
nm
nm
cuvett
width
mm
faruv
cd
spectrum
data
analyz
use
cdsstr
program
dichroweb
server
whitmor
wallac
normal
root
mean
squar
deviat
calcul
evalu
good
fit
fluoresc
spectrum
protein
dissolv
mm
phosphat
buffer
ph
guanidin
hydrochlorid
monitor
use
perkinelm
luminesc
spectromet
excit
wavelength
nm
emiss
spectrum
scan
nm
nm
measur
maxim
peak
intens
use
identifi
conform
chang
auc
experi
perform
xla
analyt
ultracentrifug
beckman
coulter
use
ti
rotor
sediment
veloc
sv
experi
perform
use
doublesector
epon
charcoalfil
centerpiec
rotor
speed
rpm
protein
solut
mgml
pedv
pro
catalyt
core
refer
solut
mm
triscl
ph
mm
nacl
load
centerpiec
absorb
nm
monitor
continu
time
interv
step
size
cm
multipl
scan
differ
time
interv
fit
continu
c
c
distribut
model
use
sedfit
program
schuck
dub
assay
reaction
mixtur
contain
fluorogen
substrat
ubafc
boston
biochem
sarsor
merscov
pl
pro
pedv
pro
mm
phosphat
buffer
ph
total
volum
ml
enzymat
activ
determin
monitor
excit
emiss
nm
respect
determin
inhibitori
effect
veloc
data
variou
concentr
inhibitor
fit
obtain
ic
accord
eq
v
initi
veloc
presenc
inhibitor
concentr
v
initi
veloc
absenc
inhibitor
n
hill
constant
program
sigmaplot
systat
softwar
use
data
analysi
peptidyl
substrat
dabcylfrlkggapikgvedan
dabcylfkkkgggdvkeedan
synthes
genscript
use
measur
proteolyt
activ
pedv
pro
catalyt
core
mutant
increas
fluoresc
intens
monitor
excit
emiss
wavelength
nm
respect
perkinelm
luminesc
spectromet
fluoresc
intens
convert
concentr
hydrolyz
substrat
use
standard
curv
determin
fluoresc
measur
defin
concentr
product
kinet
analysi
reaction
mixtur
contain
peptid
substrat
mm
phosphat
buffer
ph
total
volum
ml
addit
enzym
reaction
mixtur
concentr
fluoresc
intens
monitor
increas
fluoresc
intens
linear
min
thu
slope
line
repres
initi
veloc
steadyst
kinet
paramet
determin
fit
data
michaelismenten
equat
enzym
kinet
assay
perform
method
similar
describ
peptidyl
substrat
concentr
inhibitor
concentr
veloc
data
found
best
fit
noncompetit
inhibit
model
accord
eq
k
cat
rate
constant
e
denot
enzym
substrat
inhibitor
concentr
respect
k
micha
constant
interact
peptid
substrat
enzym
k
inhibit
constant
model
structur
pedv
pro
gener
swissmodel
arnold
et
al
molecular
dock
perform
use
autodock
vina
trott
olson
sever
grid
box
x
differ
center
coordin
set
cover
entir
put
structur
dock
paramet
set
default
best
model
coordin
set
list
inspect
model
score
best
among
set
select
final
bind
model
initi
attempt
express
pedv
pro
includ
ubl
catalyt
domain
polyprotein
residu
either
ntermin
ctermin
histag
success
previou
studi
suggest
ubl
domain
involv
catalyt
activ
sarsand
merscov
pl
pro
chou
et
al
clasman
et
al
therefor
remov
ubl
domain
appli
sumo
fusion
protein
nterminu
catalyt
core
residu
enhanc
solubl
fortun
possibl
express
pedv
pro
catalyt
core
e
coli
purifi
follow
remov
sumo
purif
use
sizeexclus
chromatographi
highli
pure
pro
obtain
fig
left
panel
lane
mass
spectrometri
perform
identifi
sequenc
recombin
protein
total
peptid
origin
pedv
pro
identifi
fig
right
panel
align
peptid
pedv
pro
sequenc
show
coverag
nterminu
cterminu
protein
confirm
fig
bottom
panel
first
time
pure
pedv
pro
obtain
secondari
tertiari
quaternari
structur
analyz
cd
spectrometri
analysi
spectrum
cdsstr
fig
show
pedv
pro
consist
random
coil
proport
similar
sarscov
pl
pro
core
residu
consist
random
coil
data
shown
comparison
previou
studi
suggest
merscov
pl
pro
consist
random
coil
higher
content
inclus
ubl
domain
lin
et
al
result
suggest
three
coronavir
pl
pro
show
similar
secondari
structur
content
protein
emiss
use
reveal
tertiari
conform
chang
absenc
presenc
denatur
fig
result
demonstr
fluoresc
emiss
pedv
pro
phosphat
buffer
nativ
form
show
major
broad
peak
nm
split
two
peak
nm
nm
guanidin
hydrochlorid
two
peak
match
maxim
emiss
wavelength
tyrosin
tryptophan
respect
result
suggest
addit
denatur
induc
exposur
hydrophob
core
protein
similar
foldingunfold
chang
maxim
emiss
wavelength
also
observ
case
sarscov
pl
pro
albeit
fluoresc
intens
denatur
pedv
pro
higher
nativ
enzym
chou
et
al
previou
studi
stabil
core
domain
suggest
higher
fluoresc
intens
denatur
aggreg
bullock
et
al
sv
experi
carri
determin
quaternari
structur
pedv
pro
fig
use
continu
c
c
distribut
analysi
found
one
major
peak
sediment
coeffici
molecular
weight
kda
fig
valu
close
predict
monomer
mass
kda
previou
studi
use
sv
experi
suggest
sarsand
merscov
pl
pro
also
monom
lin
et
al
overal
secondari
tertiari
quaternari
structur
pedv
pro
catalyt
core
similar
sarsand
merscov
pl
pro
even
though
sequenc
ident
fig
next
order
compar
dub
activ
pedv
pro
coronavir
pl
pro
activ
assay
use
ubafc
substrat
carri
activ
determin
normal
give
fold
increas
dub
activ
pedv
pro
fig
result
show
sarsand
merscov
pl
pro
similar
dub
activ
surprisingli
given
substrat
concentr
pedv
pro
show
activ
compar
two
pl
pro
onefortieth
protein
concentr
indic
pedv
pro
consider
greater
dub
activ
furthermor
sequenc
align
indic
pedv
pro
may
also
zinc
finger
motif
like
coronavir
pl
pro
fig
green
oval
baileyelkin
et
al
lei
et
al
ratia
et
al
wojdyla
et
al
previou
studi
shown
dub
activ
coronavir
pl
pro
inhibit
addit
chelat
like
edta
remov
intrins
zinc
ion
chou
et
al
lin
et
al
line
expect
inhibit
pedv
pro
edta
display
similar
dosedepend
pattern
suggest
remov
endogen
metal
ion
inhibit
pedv
pro
fig
furthermor
like
coronavir
pl
pro
pedv
pro
inhibit
ad
extra
extern
zinc
ion
chou
et
al
lin
et
al
addit
proteolyt
activ
pedv
pro
investig
use
fluorogen
peptidyl
substrat
tabl
comparison
use
peptidyl
substrat
sequenc
match
residu
cleavag
site
sarscov
pl
pro
frlkgg
peptidyl
substrat
optim
pedv
pro
whose
cleavag
site
residu
fkkkgg
base
nonstructur
protein
nsp
cleavag
site
genbank
access
number
interestingli
less
satur
observ
use
optim
peptidyl
substrat
fig
fail
improv
due
fact
proteolyt
activ
concentr
substrat
higher
appropri
measur
innerfilt
effect
fit
data
michaelismenten
equat
k
k
cat
min
sarscovderiv
substrat
k
k
cat
min
optim
substrat
determin
tabl
optim
substrat
show
higher
k
cat
k
result
higher
k
higher
k
cat
compar
sarscovderiv
substrat
dissimilar
kinet
paramet
two
peptidyl
substrat
suggest
pedv
pro
may
recogn
variou
residu
beta
cov
lfvg
alpha
cov
kra
contrast
sarscov
pl
pro
hydrophob
subsit
result
cleav
pedvoptim
substrat
substrat
ibv
whose
residu
also
lysin
han
et
al
lei
et
al
wojdyla
et
al
furthermor
contrast
consider
greater
dub
activ
k
cat
pedv
pro
optim
peptidyl
substrat
lower
sarscov
pl
pro
lin
et
al
inconsist
efficaci
dub
proteolyt
activ
indic
pedv
pro
like
usp
enzym
avvakumov
et
al
renatu
et
al
previou
studi
suggest
pedv
pro
pro
interferon
antagonist
via
dub
activ
xing
et
al
addit
recent
review
suggest
pro
pro
alpha
cov
may
show
differ
level
effici
cleav
nsp
site
lei
et
al
previou
studi
sarscov
pl
pro
demonstr
oxyanion
within
hydrogenbond
distanc
side
chain
catalysi
ratia
et
al
although
conserv
mutat
equival
residu
merscov
pl
pro
tryptophan
show
increas
k
cat
lin
et
al
accord
sequenc
align
equival
residu
pedv
pro
fig
purpl
oval
verifi
mutant
produc
kinet
paramet
character
use
two
peptidyl
substrat
fig
tabl
interestingli
use
sarscovderiv
substrat
produc
increas
activ
base
k
cat
k
result
increas
k
increas
k
cat
result
demonstr
mutat
enhanc
hydrolysi
sarscovderiv
peptidyl
substrat
contrast
signific
differ
hydrolysi
optim
substrat
wildtyp
pedv
pro
mutant
tabl
result
indic
exist
residu
may
quit
enough
support
proteolyt
abil
structur
inform
pedv
pro
complex
ub
optim
peptidyl
substrat
requir
demonstr
detail
catalyt
mechan
especi
format
oxyanion
hole
sever
coronavir
pl
pro
inhibitor
identifi
previou
studi
chen
et
al
cheng
et
al
chou
et
al
lin
et
al
ratia
et
al
present
studi
compound
screen
determin
whether
inhibit
pedv
pro
tabl
among
compound
two
thiopurin
analog
found
abl
inhibit
dub
activ
pedv
pro
ic
respect
fig
tabl
ic
lower
suggest
amino
group
may
play
role
activ
pharmacophor
inhibit
addit
two
analog
hypoxanthin
also
use
structurefunct
relationship
studi
found
replac
thiocarbonyl
group
either
hydroxyl
methylthio
group
result
compound
devoid
inhibitori
activ
suggest
import
inhibit
tabl
due
higher
inhibit
capabl
chosen
investig
kinet
assay
variou
concentr
peptidyl
substrat
carri
investig
inhibit
mechan
fig
interestingli
observ
kinet
paramet
show
decreas
appar
k
cat
increas
concentr
wherea
appar
k
affect
significantli
clearli
indic
noncompetit
pattern
inhibit
inde
data
found
best
fit
noncompetit
inhibit
model
k
fig
tabl
result
suggest
peptidyl
substrat
may
bind
differ
site
comparison
show
competit
inhibitori
effect
sarsand
merscov
pl
pro
chou
et
al
show
noncompetit
inhibitori
effect
human
chuang
et
al
albeit
k
close
result
indic
broad
spectrum
inhibitor
human
viral
dub
enzym
via
differ
mechan
noncompetit
inhibitor
pedv
pro
recognit
bind
site
allow
us
understand
inhibitori
mechan
clearli
detail
structur
inform
inhibit
pedv
pro
mm
edta
zn
also
measur
activ
data
set
normal
pedv
pro
avail
gener
structur
model
pedv
pro
tri
discov
put
bind
site
use
silico
dock
interestingli
surprisingli
found
put
bind
site
highest
affin
score
near
activ
site
left
side
block
loop
residu
ubiquitin
ctermin
tail
locat
right
side
fig
model
polar
interact
residu
block
loop
show
hydrophob
contact
bind
site
may
render
block
loop
less
flexibl
therefor
disfavor
catalysi
seri
noncoval
inhibitor
compound
show
similar
block
effect
although
competit
inhibitor
bind
subsit
ratia
et
al
comparison
besid
residu
align
show
sequenc
ident
put
bind
residu
fig
red
oval
furthermor
region
occupi
residu
sarscov
pl
pro
residu
merscov
pl
pro
fig
indic
bind
site
may
exist
pedv
pro
contrast
previou
studi
suggest
bind
site
sarsand
merscov
pl
pro
may
near
catalyt
triad
cystein
residu
due
competit
pattern
inhibit
chou
et
al
studi
provid
first
descript
express
purif
structur
properti
pedv
pro
well
potent
inhibit
thiopurin
analog
broad
spectrum
inhibitor
found
abl
inhibit
dub
activ
also
proteolyt
activ
pedv
pro
result
shed
light
possibl
inhibit
pedv
infect
small
molecul
instead
antibodi
furthermor
base
noncompetit
inhibitori
effect
propos
alloster
bind
site
stabil
block
loop
near
activ
site
result
inhibit
present
studi
suggest
may
suitabl
lead
compound
b
proteolyt
activ
variou
concentr
sarscovderiv
peptidyl
substrat
measur
fig
fig
appar
k
determin
best
global
fit
data
noncompetit
inhibit
model
eq
r
sqr
c
nd
ic
determin
due
lack
inhibit
compound
concentr
r
sqr
valu
kinet
paramet
best
fit
shown
tabl
assay
repeat
ensur
reproduc
antivir
drug
develop
